-+ 0.00%
-+ 0.00%
-+ 0.00%

ASSEMBLY BIOSCIENCES DOSES FIRST TWO PARTICIPANTS IN PHASE 2 STUDY OF ORAL NTCP INHIBITOR ABI-6250 FOR CHRONIC HEPATITIS DELTA VIRUS

Reuters·10/29/2026 20:00:00

Please log in to view news